Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

G-rich motifs within phosphorothioate-based antisense oligonucleotides (ASOs) drive activation of FXN expression through indirect effects

Nucleic Acids Research(2022)10.1093/nar/gkac1108Source: DataRank Database

G-rich motifs within phosphorothioate-based antisense oligonucleotides (ASOs) drive activation of FXN expression through indirect effects is a research paper published in Nucleic Acids Research (2022). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

Linked data & code

geo igsr

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: goldTopics (36)IDs (PubMed, PMC)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Ezequiel Calvo-Roitberg ORCID,Julia M Rembetsy-Brown,Minggang Fang ORCID,Jacquelyn Sousa ORCID,Zachary J. Kartje ORCID

Live enrichment

PubMed:36511872 PMC:PMC9825156

National Institutes of Health

Grant: R01 NS111990

National Institutes of Health

Grant: R01 NS114052

NIGMS NIH HHS

Grant: R35 GM133762

National Institutes of Health

Grant: 5R01NS111990-03

Next-generation antisense therapeutics for ALS and frontotemporal dementia

National Institutes of Health

Grant: 5R01NS114052-04

Transcriptional Upregulation of the Epigenetically Repressed FXN Gene as a Therapeutic Approach for Friedreich Ataxia

Ono Pharma Foundation

Friedreich's Ataxia Research Alliance

goldLicense: cc-by

publisherhttps://academic.oup.com/nar/article-pdf/50/22/12657/48489055/gkac1108.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9825156

Europe_PMChttps://europepmc.org/articles/PMC9825156

Europe_PMChttps://europepmc.org/articles/PMC9825156?pdf=render

https://doi.org/10.1093/nar/gkac1108

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

Cells, CulturedHumansFriedreich AtaxiaIron-Binding ProteinsDNA-Binding ProteinsOligonucleotides, AntisenseRNA, MessengerGene Expression RegulationFrataxin

Keywords

570Medical SciencesBioinformaticsCellsMessengerOligonucleotides610Biomedical InformaticsChemical Biology and Nucleic Acid ChemistryIron-Binding ProteinsMedical SpecialtiesMedicine and Health SciencesHumansRNA, MessengerAntisenseCells, CulturedCulturedFrataxinOligonucleotides, AntisenseDNA-Binding ProteinsOncologyGene Expression RegulationFriedreich AtaxiaRNA

G-rich motifs within phosphorothioate-based antisense oligonucleotides (ASOs) drive activation of FXN expression through indirect effects

FAIR Checklist

Authors (11)

Funding (7 grants)

Open Access

Topics

Annotations (Europe PMC)